BridgeBio Pharma (BBIO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on BridgeBio Pharma (BBIO) is Neutral.

The composite score behind that read is -0.06, weighing +0.11 of bullish evidence against -0.27 bearish.

BridgeBio Pharma last closed at $65.35, +0.48% on the session.

Against the IVW growth benchmark the position is -0.32% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

4 graded predictions for BBIO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks BridgeBio Pharma in the 88th percentile on return on equity, where 100 is best.

BridgeBio Pharma is classified under Health Care / Biotechnology, with a market capitalisation of $12.71B.

StockMap tracks BridgeBio Pharma as the 22nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite BridgeBio Pharma ranks 146th of 381 in the group, against a group median of -0.08.